

Press Release

Zug, 29 May 2012

Annual Report 2011/2012 and invitation to the ordinary Shareholders' Meeting

Today, HBM BioVentures sent to its shareholders the Annual Report for the financial year 2011/2012 and the invitation to the eleventh ordinary Shareholders' Meeting on the 22 June 2012, with the following agenda:

- 1. Annual report, statutory financial statements and consolidated financial statements 2011/2012; reports of the auditors**
- 2. Discharge from liability of the members of the Board of Directors and of the Management**
- 3. Appropriation of results**
- 4. Elections to the Board of Directors**

The terms of office of Mr Hans Peter Hasler, Dr Rudolf Lanz and Mr Robert A. Ingram end at the forthcoming Ordinary Shareholders' Meeting. All of them stand for re-election. Based on the suggestion of the largest shareholder, Astellas, the Board of Directors proposes the first-time election of Mr Mario Germano Giuliani as a new member of the Board of Directors.

Mr Mario Germano Giuliani (born 1972) holds a degree in Economy and Commerce. Mr. Giuliani has been working in the family owned business Giuliani SpA in Milan (Italy) for the past 15 years during which he has been involved in all business areas such as marketing & sales, finance & controlling as well as the management. Since 2001 he serves as CEO and since 2003 he is Chairman of the Board of Directors. Since Mr. Giuliani became the CEO, he built and expanded the business further and multiplied the turnover. Before joining the family business he was working with an US based asset management company.

Mr Giuliani serves as a member of the Investment Committee of Mosaix Ventures, LLP, Toronto, Canada (Since 2000), as a member of the Board of Directors of Royalty Pharma in New York, USA (since 2001) and also as a member of the Board of Directors of the listed pharma company Recordati SpA in Milan (since 2011).

NOT FOR DISTRIBUTION IN USA, CANADA, JAPAN OR AUSTRALIA

HBM BioVentures

The Board of Directors is convinced that Mr Giuliani, with his qualification and experience, would further strengthen the Board of Directors.

5. Election of the auditor

Re-election of Ernst & Young AG, Zurich, as auditor of the statutory financial statements and the consolidated financial statements for the 2012/2013 business year.

6. Reduction of the share capital (cancellation of own shares)

As part of the 2009 share buy-back programme, the Company had acquired a total of 597'345 of its own shares via the second trading line on SIX Swiss Exchange. The shares correspond to 6.1% of the issued shares. The Board of Directors intends to propose the cancellation of the shares that have already been acquired, plus any further shares that may be repurchased under this share buy-back programme up to 21 June 2012. However, the number of shares to be cancelled will be rounded down to the nearest hundred thousand, but will not exceed 700,000 registered shares.

7. Approval of a new share buy-back programme and capital reduction

With the 2012 buy-back programme, the Board of Directors would like to keep open the option of repurchasing up to 10% of issued shares via the second trading line in order to cancel them as part of a capital reduction. These buy-backs shall be effected in the future depending on how business, disposable liquidity and the markets develop.

8. Change of name to “HBM Healthcare Investments AG”

The company operates since its foundation in 2001 under the name of „HBM BioVentures Ltd“. Today's portfolio has matured and actually consists of around 60% of investments in companies, which are already profitable or with products on the market. Based on the Investment Guidelines, adopted by the Board of Directors in June 2010, forthcoming investment activities shall focus more on companies with predictable business growth and less on traditional venture capital financing. The name change would reflect the broadening of the investment segment.

9. Miscellaneous

The detailed invitation to the eleventh ordinary shareholders' meeting and the annual report for the financial year 2011/2012 are attached to this message and available via the HBM BioVentures website www.hbmbioventures.com.

For further information, please contact Dr Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, andreas.wicki@hbmbioventures.com.

HBM BioVentures Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmbioventures.com
www.hbmbioventures.com

NOT FOR DISTRIBUTION IN USA, CANADA, JAPAN OR AUSTRALIA

HBM BioVentures

Profile of HBM BioVentures AG

HBM BioVentures invests in the healthcare sector. The Company holds and manages an international portfolio of some twenty five promising companies in the biotechnology/human medicine, medical technology and diagnostics sectors. Many of these companies have their lead products already available on the market, or at an advanced stage of development. The focus of investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM BioVentures an interesting alternative to investing in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmbioventures.com
www.hbmbioventures.com